Risk factors for hyperglycemia in extremely low birth weight infants during the first 14 days.
- 2022-01
- Pediatrics and neonatology 63(1)
- Yuka Inage
- Daishi Hirano
- Ai Nakagawa
- Saya Yamada
- Yuko Kotake
- Naohiro Ikoma
- Kensuke Kumazawa
- Shion Hayashi
- Yukitoshi Tanabe
- Masahisa Kobayashi
- Masaki Shimizu
- PubMed: 34330686
- DOI: 10.1016/j.pedneo.2021.07.001
Study Design
- Type
- Observational
- Sample size
- n = 23
- Population
- 55 ELBWIs (32 male infants)
- Methods
- retrospectively evaluated 55 ELBWIs between January 2015 and March 2020; Cox proportional hazards regression analysis
- Duration
- first 14 days of life
- Funding
- Unclear
Background
There are limited data regarding the risk factors for hyperglycemia in extremely low birth weight infants (ELBWIs). The aim of this observational study was to investigate the incidence of hyperglycemia among ELBWIs during the first 14 days of life and identify independent risk factors for hyperglycemia development.Methods
We retrospectively evaluated 55 ELBWIs (32 male infants) between January 2015 and March 2020. Hyperglycemia was diagnosed when the glucose level was ≥180 mg/dL. Demographic and clinical data were extracted from the patients' medical records. The risk factors associated with the onset of hyperglycemia were identified by Cox proportional hazards regression analysis with variables that had previously been identified as risk factors for hyperglycemia.Results
Hyperglycemia developed in 23 patients (41.8%) within the first 14 days of life. Gestational age, chorioamnionitis, postnatal intravenous glucocorticoids, and probiotic type were included in the analysis. The results indicated that hyperglycemia was significantly associated with gestational age (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.48-0.87; P = 0.004). Further, Bifidobacterium breve (B. breve M-16V) use was related to hyperglycemia in ELBWIs (HR, 2.95; 95% CI, 1.10-7.87; P = 0.031).Conclusion
Hyperglycemia was strongly associated with lower gestational age and B. breve M-16V use in our study population. Although probiotic supplementation may be beneficial for preterm infants to reduce the incidence of necrotizing enterocolitis, the dextrin used as an excipient in B. breve M-16V may lead to an undesirable carbohydrate load in ELBWIs.Research Insights
Further, Bifidobacterium breve (B. breve M-16V) use was related to hyperglycemia in ELBWIs (HR, 2.95; 95% CI, 1.10-7.87; P=0.031).
- Effect
- Harmful
- Effect size
- Large